Roch Doliveux Acquires 20,250 Shares of Oxford Biomedica (LON:OXB) Stock

Key Points

• Insider purchase: Roch Doliveux bought 20,250 Oxford Biomedica shares at GBX 505 each, for a total investment of £102,262.50.
• Weak financial performance: Oxford Biomedica reported quarterly EPS of GBX (30.39), alongside a negative net margin of 23.23% and negative return on equity of 54.51%.
• Analyst sentiment remains positive: Four analysts rate the stock a Buy and one rates it Hold, giving Oxford Biomedica a “Moderate Buy” consensus and an average price target of GBX 580.85.

Oxford Biomedica plc (LON:OXB - Get Free Report) insider Roch Doliveux purchased 20,250 shares of the business's stock in a transaction on Wednesday, September 23rd. The stock was purchased at an average cost of GBX 505 per share, with a total value of £102,262.50.

Oxford Biomedica Price Performance

Shares of LON:OXB traded up GBX 11 on Thursday, hitting GBX 492. The company's stock had a trading volume of 15,364,758 shares, compared to its average volume of 1,184,215. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67. The company has a 50-day simple moving average of GBX 512.48 and a 200 day simple moving average of GBX 576.03. The company has a market capitalization of £595.56 million, a PE ratio of -18.28 and a beta of 1.09. Oxford Biomedica plc has a 1 year low of GBX 420 and a 1 year high of GBX 952.

Oxford Biomedica (LON:OXB - Get Free Report) last posted its quarterly earnings data on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. Sell-side analysts forecast that Oxford Biomedica plc will post -31.0799998 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the company. Royal Bank Of Canada reiterated an "outperform" rating and set a GBX 900 target price on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a GBX 595 price target on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Oxford Biomedica presently has an average rating of "Moderate Buy" and an average price target of GBX 580.85.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.